Semax 10mg

Semax is a synthetic heptapeptide derived from the 4-10 region of adrenocorticotropic hormone (ACTH), with a terminal Pro-Gly-Pro modification that significantly extends its half-life. It was developed at the Institute of Molecular Biology of the Russian Academy of Sciences in the 80s and is one of the most-studied peptide nootropics in the scientific literature.

Molecular structure:

• Met-Glu-His-Phe-Pro-Gly-Pro
• Molecular weight: 813.9 Da
• Average half-life: 60 to 90 minutes (significantly longer than the original ACTH 4-10)
• Valid routes of administration: intranasal and subcutaneous

Unlike full-length ACTH, Semax lacks activity on the adrenal cortex, eliminating effects on cortisol and aldosterone and leaving only the neuroactive action.

• Increased BDNF and NGF: Semax stimulates the brain's expression of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF), key factors for synaptic plasticity.
• Neurotransmitter Modulation increases dopaminergic and serotonergic tone in specific regions, without causing massive release
• Inhibition of enkephalins and endorphins: protect these endogenous opioids from enzymatic degradation
• Neuroprotective action reduce neuronal damage in models of cerebral ischemia
• Melanocortin receptor activation contributes to the regulation of alertness and attention

• Post-ischemic stroke recovery (clinical use approved in Russia)
• Memory and learning enhancement in healthy adults
• Attention deficit disorder (ADHD)
• Cognitive fatigue and burnout
• Post-traumatic brain injury recovery
• Research in mild cognitive impairment and early dementia
• Performance improvement in demanding cognitive tasks

Reconstitution: add 2 ml of bacteriostatic water to the 10 mg vial. Concentration: 5,000 mcg/ml.

Routes of administration:

• Subcutaneous standard route of administration for Elyx Aminos compounds.
• Note: the literature also describes the intranasal route for its CNS bioavailability; it is documented here as a bibliographic reference.

Excellent safety profile documented in decades of Russian clinical use. Rare adverse events: local nasal irritation with prolonged intranasal use, mild headache, insomnia if administered late in the day.

Avoid in patients with bipolar disorder or active psychosis due to its dopaminergic action. Do not combine with MAOIs or dopamine reuptake inhibitors without supervision.

• Cognition + emotional stability Semax + Selank (classic Russian combination)
• Neurological Recovery Semax + NAD+ for cerebral mitochondrial support
• Integral burnout: Semax + Selank + DSIP for focus, calm, and sleep

1. Asmarin IP, Nezavibatko VN, Myasoedov NF, et al. A nootropic adrenocorticotropin analog 4-10-Semax: 15 years experience in development and study. J Higher Nervous Activity I P Pavlov. 1997;47(2):420-430.
2. Dolotov OV, Karpenko EA, Inozemtseva LS, et al. Semax, an analog of adrenocorticotropin (4-10), specifically binds and increases brain-derived neurotrophic factor protein levels in the rat basal forebrain. J Neurochem. 2006;97(Suppl 1):82-86.
3. Shadrina MI, Dolotov OV, Grivennikov IA, et al. Rapid induction of neurotrophin mRNAs in rat glial cell cultures by Semax, an adrenocorticotropic hormone analog. Neurosci Lett. 2001;308(2):115-118.